Sartorius will use Crucell’s key technology to evaluate monoclonal antibodies produced using PER.C6 cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant monoclonal antibodies.
Crucell and Sartorius further agreed to expand their PER.C6 collaboration by sharing technology and data on antibody production. Financial details were not disclosed.
Crucell’s and DSM’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6 technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions, said Crucell.